ArticleBMJ neurology open2026

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease.

Alok K Dwivedi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.